IL311364A - Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers - Google Patents
Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancersInfo
- Publication number
- IL311364A IL311364A IL311364A IL31136424A IL311364A IL 311364 A IL311364 A IL 311364A IL 311364 A IL311364 A IL 311364A IL 31136424 A IL31136424 A IL 31136424A IL 311364 A IL311364 A IL 311364A
- Authority
- IL
- Israel
- Prior art keywords
- ovarian
- cancers
- treatment
- receptor modulators
- glucocorticoid receptor
- Prior art date
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000002611 ovarian Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163244825P | 2021-09-16 | 2021-09-16 | |
PCT/US2021/050617 WO2023043444A1 (en) | 2021-09-16 | 2021-09-16 | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers |
US202263324873P | 2022-03-29 | 2022-03-29 | |
US202263345682P | 2022-05-25 | 2022-05-25 | |
PCT/US2022/042475 WO2023043632A1 (en) | 2021-09-16 | 2022-09-02 | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
IL311364A true IL311364A (en) | 2024-05-01 |
Family
ID=85603418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL311364A IL311364A (en) | 2021-09-16 | 2022-09-02 | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4401734A1 (ko) |
JP (1) | JP2024534456A (ko) |
KR (1) | KR20240063962A (ko) |
AU (1) | AU2022344984A1 (ko) |
CA (1) | CA3230034A1 (ko) |
IL (1) | IL311364A (ko) |
MX (1) | MX2024003254A (ko) |
WO (1) | WO2023043632A1 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017216772A2 (en) * | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
WO2019200156A1 (en) * | 2018-04-11 | 2019-10-17 | Oric Pharmaceuticals, Inc. | Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof |
US11234971B2 (en) * | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
WO2021163273A1 (en) * | 2020-02-12 | 2021-08-19 | Oric Pharmaceuticals, Inc. | Uses of glucocorticoid receptor antagonists |
-
2022
- 2022-09-02 MX MX2024003254A patent/MX2024003254A/es unknown
- 2022-09-02 WO PCT/US2022/042475 patent/WO2023043632A1/en active Application Filing
- 2022-09-02 KR KR1020247012497A patent/KR20240063962A/ko active Search and Examination
- 2022-09-02 AU AU2022344984A patent/AU2022344984A1/en active Pending
- 2022-09-02 JP JP2024516978A patent/JP2024534456A/ja active Pending
- 2022-09-02 EP EP22870514.1A patent/EP4401734A1/en active Pending
- 2022-09-02 IL IL311364A patent/IL311364A/en unknown
- 2022-09-02 CA CA3230034A patent/CA3230034A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3230034A1 (en) | 2023-03-23 |
KR20240063962A (ko) | 2024-05-10 |
JP2024534456A (ja) | 2024-09-20 |
WO2023043632A1 (en) | 2023-03-23 |
AU2022344984A1 (en) | 2024-03-14 |
MX2024003254A (es) | 2024-04-03 |
EP4401734A1 (en) | 2024-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265217A (en) | Modulators of glucocorticoid receptors and their use in the treatment of pancreatic cancer | |
IL269725B (en) | Use of glucocorticoid receptor modulators to treat cervical cancer | |
IL268011A (en) | Modulators of estrogen receptor proteolysis and related methods of use | |
IL282257A (en) | Androgen receptor modulators and methods of using them | |
EP3912714A4 (en) | CHILE RAW MATERIAL UNIFORM MIXING DEVICE | |
GEP20217271B (en) | Combination therapy for the treatment of cancer | |
PH12020551140A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12020551144A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
EP3645040A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS | |
IL269009A (en) | Simultaneous treatment with glucocorticoid receptor modulators and CYP3A inhibitors | |
MX2021015508A (es) | Carbamatos de piridina y su uso como moduladores del receptor glun2b. | |
IL288859A (en) | Converted pyrazolo-pyridine amides and their use as glun2b receptor modulators | |
IL272669A (en) | Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer | |
IL269607A (en) | Microparticles coated with minerals for prolonged delivery of biologically active molecules | |
IL311364A (en) | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers | |
IL287837A (en) | Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers | |
SI3707143T1 (sl) | Novi analogi kot androgeni receptorji in modulatorji glukokortikoidnega receptorja | |
EP3592358A4 (en) | USE OF GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF CATECHOLAMIN SECRETING TUMORS | |
GB202219507D0 (en) | Use of pyridoxal in preparation of drugs for treating ovarian cancer | |
IL289313A (en) | Treatment of pain using an allosteric modulator of trpv1 | |
IL279182A (en) | Delivery system and method for delivering tampon conductors | |
IL274007A (en) | Anti-CD3 antibody and a pharmaceutical preparation containing it for the treatment of cancer | |
EP3880709A4 (en) | ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR THE TREATMENT OF CANCER | |
PL3801854T3 (pl) | System dozujący dla mieszaniny dwóch komponentów i statyczna dysza mieszająca dla niego | |
IL274698A (en) | Combinations of IRS/STAT3 activity regulators and PD–1/PD–L1 antibodies for cancer therapy |